Black Diamond Therapeutics, Inc.
One Main Street
Cambridge
MA
02142
United States
Website: http://www.blackdiamondtherapeutics.com/
Email: info@bdtherapeutics.com
About Black Diamond Therapeutics, Inc.
Our Vision
Precision Cancer Medicines for Every Genetically-Defined Patient
Company Overview
Black Diamond Therapeutics: A Next-Wave Cancer Precision Medicine Company
Black Diamond Therapeutics has pioneered the development of selective medicines for patients with genetically-defined cancers driven by oncogenes activated by allosteric mutations.
The cornerstone of our approach derives from evolving trends in cancer clinical medicine. Genome-wide information – now routinely obtained from DNA testing of cancer patients – identifies clusters of uncharacterized genomic alterations. Today, new baskets of un-drugged oncogenic targets exist, leading to the identification of additional cancer patients in need of novel therapies.
Using our MAP platform, Black Diamond Therapeutics is pioneering new ways to functionally assess the mutational landscape of individual oncogenes – to discover and validate new targets, and to develop novel approaches to creating highly selective therapeutics.
74 articles with Black Diamond Therapeutics, Inc.
-
Tangles of toxic proteins are associated with various dementias, such as Alzheimer's disease. Often, these tangles are misfolded proteins. Now, researchers have identified a new mechanism that might reverse the build-up of these aggregates.
-
Black Diamond Therapeutics Announces Publication of New Computational and Functional Analyses of HER2 Mutations Based on its Proprietary MAP Discovery Engine
5/12/2022
Black Diamond Therapeutics, Inc. announced the publication of data identifying new oncogenic HER2 allosteric mutations that support the Mutation-Allostery-Pharmacology discovery engine’s capabilities and further suggest the need for novel inhibitors to treat HER2-mutant cancers.
-
Black Diamond Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/11/2022
Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
-
The first quarter hasn't been kind to international biopharmaceutical firms. BioSpace takes a look at the fates of Saniona and Black Diamond below.
-
Black Diamond Therapeutics Announces Pipeline Prioritization and Workforce Realignment
4/25/2022
Black Diamond Therapeutics, Inc. today announced that it is realigning its resources to focus on key near-term value drivers and to extend its cash runway into the third quarter of 2024, supporting the execution of important clinical and preclinical milestones.
-
AstraZeneca and Daiichi Sankyo reported that their supplemental Biologics License Application (sBLA) for Enhertu was granted Priority Review by the U.S. Food and Drug Administration.
-
Black Diamond Therapeutics Announces First Patient Dosed in Phase 1 Study of BDTX-1535, a MasterKey Inhibitor of EGFR for the Treatment of Glioblastoma and Non-Small Cell Lung Cancer
4/18/2022
Black Diamond Therapeutics, Inc. announced the dosing of the first patient in the Phase 1 study evaluating BDTX-1535, a MasterKey inhibitor of epidermal growth factor receptor for the treatment of both non-small cell lung cancer and glioblastoma derived from Black Diamond’s MAP discovery engine.
-
Black Diamond Therapeutics to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference
4/7/2022
Black Diamond Therapeutics, Inc. announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the Canaccord Genuity Horizons in Oncology Virtual Conference being held on Thursday, April 14, 2022 at 10:00 a.m. ET.
-
Black Diamond Therapeutics Appoints Wendy L. Dixon to its Board of Directors
4/7/2022
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the appointment of Wendy L. Dixon, Ph.D., to its Board of directors.
-
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
3/17/2022
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.
-
Black Diamond Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference
3/2/2022
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will participate in a panel discussion on lung cancer at the Cowen 42nd Annual Health Care Conference.
-
BioSpace Movers & Shakers, Feb. 25
2/25/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Black Diamond Therapeutics Appoints Elizabeth Montgomery as Chief People Officer
2/22/2022
Black Diamond Therapeutics, Inc. today announced the appointment of Elizabeth Montgomery as its first Chief People Officer.
-
Clinical Catch-Up: January 10-14
1/17/2022
Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look. -
Black Diamond Therapeutics Announces FDA Allowance of IND Application for BDTX-1535, A MasterKey Inhibitor of EGFR for the Treatment of Gliobastoma and Non-Small Cell Lung Cancer
1/11/2022
Black Diamond Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for its MasterKey inhibitor BDTX-1535.
-
Black Diamond Therapeutics Announces Strategic Priorities and Expected Milestones for 2022
1/10/2022
Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, announced a strategic pipeline update and outlined its expected upcoming milestones.
-
Black Diamond Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/5/2022
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the 40th Annual J.P. Morgan Healthcare Conference.
-
Black Diamond Therapeutics to Present at Upcoming Investor Conferences - Nov 08, 2021
11/8/2021
Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s progress at the following upcoming investor conferences.
-
Black Diamond Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
11/8/2021
Black Diamond Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
-
Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535, BRAF, and FGFR Programs at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/8/2021
Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, announced the presentation of preclinical data for three early-stage pipeline programs in oral and poster sessions at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.